Research
Hormonal
Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.
Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.
StrongSupportsmedium confidence
Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.
Why this rating
Supported by randomized clinical trials and real-world studies.
Source
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey et al. · Peptides · 2025
DOI 10.1016/j.peptides.2025.171380
reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →